DNA vaccination: Using the patient's immune system to overcome cancer

Clinical and Developmental Immunology

Volumn 2010, Issue , 2010, Pages

  Eschenburg, Georg ^a   Stermann, Alexander ^a   Preissner, Robert ^a   Meyer, Hellmuth Alexander ^a   Lode, Holger N ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ANTIANDROGEN; ANTINEOPLASTIC AGENT; CH14.18 ANTIBODY; DNA VACCINE; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MELAN A; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; MONOPHENOL MONOOXYGENASE; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE STEM CELL ANTIGEN; UNCLASSIFIED DRUG; CANCER VACCINE; DNA; TUMOR ANTIGEN;

CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; DRUG MECHANISM; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; MELANOMA; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; CELLULAR IMMUNITY; GENETICS; HUMORAL IMMUNITY; IMMUNOLOGY; NEOPLASM; VACCINATION;

ANTIGENS, NEOPLASM; CANCER VACCINES; DNA, NEOPLASM; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; NEOPLASMS; VACCINATION; VACCINES, DNA;

EID: 79251538904     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2010/169484     Document Type: Review

References (171)

1. Jemal A., Siegel R., Xu J., Ward E., Cancer statistics, 2010 Cancer Journal for Clinicians 2010 60 5 277 300
2. Heron M., Hoyert D. L., Murphy S. L., Xu J., Kochanek K. D., Tejada-Vera B., Deaths: final data for 2006 National Vital Statistics Reports 2009 57 14 1 134
3. Stewart T. J., Abrams S. I., How tumours escape mass destruction Oncogene 2008 27 45 5894 5903
4. Elrefaei M., Blank K. J., Murasko D. M., Decreased IL-2, IFN-, and IL-10 production by aged mice during the acute phase of E55+ retrovirus infection Virology 2002 299 1 8 19
5. Kapasi Z. F., Murali-Krishna K., McRae M. L., Ahmed R., Defective generation but normal maintenance of memory T cells in old mice European Journal of Immunology 2002 32 6 1567 1573
6. Naito Y., Saito K., Shiiba K., Ohuchi A., Saigenji K., Nagura H., Ohtani H., CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer Cancer Research 1998 58 16 3491 3494
7. Zhang L., Conejo-Garcia J. R., Katsaros D., Gimotty P. A., Massobrio M., Regnani G., Makrigiannakis A., Gray H., Schlienger K., Liebman M. N., Rubin S. C., Coukos G., Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer New England Journal of Medicine 2003 348 3 203 213
8. Birkeland S. A., Storm H. H., Lamm L. U., Barlow L., Blohme I., Forsberg B., Eklund B., Fjeldborg O., Friedberg M., Frodin L., Glattre E., Halvorsen S., Holm N. V., Jakobsen A., Jorgensen H. E., Ladefoged J., Lindholm T., Lundgren G., Pukkala E., Cancer risk after renal transplantation in the nordic countries, 19641986 International Journal of Cancer 1995 60 2 183 189
9. Penn I., Malignant melanoma in organ allograft recipients Transplantation 1996 61 2 274 278
10. Ward S., Casey D., Labarthe M.-C., Whelan M., Dalgleish A., Pandha H., Todryk S., Immunotherapeutic potential of whole tumour cells Cancer Immunology, Immunotherapy 2002 51 7 351 357
11. Houghton A. N., Cancer antigens: immune recognition of self and altered self Journal of Experimental Medicine 1994 180 1 1 4
12. Liu M. A., Ulmer J. B., Human clinical trials of plasmid DNA vaccines Advances in Genetics 2005 55 25 40
13. Leitner W. W., Ying H., Restifo N. P., DNA and RNA-based vaccines: principles, progress and prospects Vaccine 1999 18 9-10 765 777
14. Leitner W. W., Hwang L. N., De Veer M. J., Zhou A., Silverman R. H., Williams B. R. G., Dubensky T. W., Ying H., Restifo N. P., Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways Nature Medicine 2003 9 1 33 39
15. Ying H., Zaks T. Z., Wang R.-F., Irvine K. R., Kammula U. S., Marincola F. M., Leitner W. W., Restifo N. P., Cancer therapy using a self-replicating RNA vaccine Nature Medicine 1999 5 7 823 827
16. Ginsberg B. A., Gallardo H. F., Rasalan T. S., Adamow M., Mu Z., Tandon S., Bewkes B. B., Roman R. -A., Chapman P. B., Schwartz G. K., Carvajal R. D., Panageas K. S., Terzulli S. L., Houghton A. N., Yuan J. D., Wolchok J. D., Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection Clinical Cancer Research 2010 16 15 4057 4065
17. Gregor P. D., Wolchok J. D., Turaga V., Latouche J.-B., Sadelain M., Bacich D., Heston W. D. W., Houghton A. N., Scher H. I., Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination International Journal of Cancer 2005 116 3 415 421
18. Huebener N., Fest S., Hilt K., Schramm A., Eggert A., Durmus T., Woehler A., Stermann A., Bleeke M., Baykan B., Weixler S., Gaedicke G., Lode H. N., Xenogeneic immunization with human tyrosine hydroxylase DNA vaccines suppresses growth of established neuroblastoma Molecular Cancer Therapeutics 2009 8 8 2392 2401
19. Wolchok J. D., Yuan J., Houghton A. N., Gallardo H. F., Rasalan T. S., Wang J., Zhang Y., Ranganathan R., Chapman P. B., Krown S. E., Livingston P. O., Heywood M., Riviere I., Panageas K. S., Terzulli S. L., Perales M. A., Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma Molecular Therapy 2007 15 11 2044 2050
20. Wolff J. A., Malone R. W., Williams P., W. C., Acsadi G., Jani A., Felgner P. L., Direct gene transfer into mouse muscle in vivo Science 1990 247 4949, part I 1465 1468
21. Renno T., Lebecque S., Renard N., Saeland S., Vicari A., What's new in the field of cancer vaccines? Cellular and Molecular Life Sciences 2003 60 7 1296 1310
22. Ciernik I. F., Berzofsky J. A., Carbone D. P., Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes Journal of Immunology 1996 156 7 2369 2375
23. Iwasaki A., Dela Cruz C. S., Young A. R., Barber B. H., Epitope-specific cytotoxic T lymphocyte induction by minigene DNA immunization Vaccine 1999 17 15-16 2081 2088
24. Rodriguez F., An L. L., Harkins S., Zhang J., Yokoyama M., Widera G., Fuller J. T., Kincaid C., Campbell I. L., Whitton J. L., DNA immunization with minigenes: low frequency of memory cytotoxic T lymphocytes and inefficient antiviral protection are rectified by ubiquitination Journal of Virology 1998 72 6 5174 5181
25. Yu Z., Karem K. L., Kanangat S., Manickan E., Rouse B. T., Protection by minigenes: a novel approach of DNA vaccines Vaccine 1998 16 17 1660 1667
26. Nkolola J. P., Wee E. G.-T., Im E.-J., Jewell C. P., Chen N., Xu X.-N., McMichael A. J., Hanke T., Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa Gene Therapy 2004 11 13 1068 1080
27. Zur Megede J., Otten G. R., Doe B., Liu H., Leung L., Ulmer J. B., Donnelly J. J., Barnett S. W., Expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 subtype B pol and gagpol DNA vaccines Journal of Virology 2003 77 11 6197 6207
28. Ulmer J. B., Donnelly J. J., Parker S. E., Rhodes G. H., Felgner P. L., Dwarki V. J., Gromkowski S. H., Deck R. R., DeWitt C. M., Friedman A., Hawe L. A., Leander K. R., Martinez D., Perry H. C., Shiver J. W., Montgomery D. L., Liu M. A., Heterologous protection against influenza by injection of DNA encoding a viral protein Science 1993 259 5102 1745 1749
29. Klinman D. M., Takeno M., Ichino M., Gu M., Yamshchikov G., Mor G., Conover J., DNA vaccines: safety and efficacy issues Springer Seminars in Immunopathology 1997 19 2 245 256
30. Disis M. L., Gooley T. A., Rinn K., Davis D., Piepkorn M., Cheever M. A., Knutson K. L., Schiffman K., Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines Journal of Clinical Oncology 2002 20 11 2624 2632
31. Heimberger A. B., Archer G. E., Crotty L. E., McLendon R. E., Friedman A. H., Friedman H. S., Bigner D. D., Sampson J. H., Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma Neurosurgery 2002 50 1 158 164
32. Ledwith B. J., Manam S., Troilo P. J., Barnum A. B., Pauley C. J., Griffiths 2nd. T. G., Harper L. B., Schock H. B., Zhang H., Faris J. E., Way P. A., Beare C. M., Bagdon W. J., Nichols W. W., Plasmid DNA vaccines: assay for integration into host genomic DNA Developments in Biologicals 2000 104 33 43
33. Manam S., Ledwith B. J., Barnum A. B., Troilo P. J., Pauley C. J., Harper L. B., Griffiths T. G. II, Niu Z., Denisova L., Follmer T. T., Pacchione S. J., Wang Z., Beare C. M., Bagdon W. J., Nichols W. W., Plasmid DNA vaccines: tissue distribution and effects of DNA sequence, adjuvants and delivery method on integration into host DNA Intervirology 2000 43 46 273 281
34. Pupa S. M., Invernizzi A. M., Forti S., Carlo E. D., Musiani P., Nanni P., Lollini P. L., Meazza R., Ferrini S., Menard S., Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat protoneu by DNA vaccination Gene Therapy 2001 8 1 75 79
35. Scanlan M. J., Gure A. O., Jungbluth A. A., Old L. J., Chen Y.-T., Cancer/testis antigens: an expanding family of targets for cancer immunotherapy Immunological Reviews 2002 188 22 32
36. Schalk J. A. C., Mooi F. R., Berbers G. A. M., Van Aerts L. A. G. J. M., Ovelgnne H., Kimman T. G., Preclinical and clinical safety studies on DNA vaccines Human Vaccines 2006 2 2 45 53
37. Soares M. M., Mehta V., Finn O. J., Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection Journal of Immunology 2001 166 11 6555 6563
38. Van der Bruggen P., Zhang Y., Chaux P., Stroobant V., Panichelli C., Schultz E. S., Chapiro J., Van den Eynde B. J., Brasseur F., Boon T., Tumor-specific shared antigenic peptides recognized by human T cells Immunological Reviews 2002 188 51 64
39. Mincheff M., Tchakarov S., Zoubak S., Loukinov D., Botev C., Altankova I., Georgiev G., Petrov S., Meryman H. T., Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial European Urology 2000 38 2 208 217
40. Rosenberg S. A., Yang J. C., Sherry R. M., Hwu P., Topalian S. L., Schwartzentruber D. J., Restifo N. P., Haworth L. R., Seipp C. A., Freezer L. J., Morton K. E., Mavroukakis S. A., White D. E., Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen Human Gene Therapy 2003 14 8 709 714
41. Tagawa S. T., Lee P., Snively J., Boswell W., Ounpraseuth S., Lee S., Hickingbottom B., Smith J., Johnson D., Weber J. S., Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma Cancer 2003 98 1 144 154
42. Timmerman J. M., Singh G., Hermanson G., Hobart P., Czerwinski D. K., Taidi B., Rajapaksa R., Caspar C. B., Van Beckhoven A., Levy R., Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma Cancer Research 2002 62 20 5845 5852
43. Drake C. G., Jaffee E., Pardoll D. M., Mechanisms of immune evasion by tumors Advances in Immunology 2006 90 51 81
44. Seliger B., Strategies of tumor immune evasion Biodrugs 2005 19 6 347 354
45. Dranoff G., GM-CSF-based cancer vaccines Immunological Reviews 2002 188 147 154
46. Jaffee E. M., Hruban R. H., Biedrzycki B., Laheru D., Schepers K., Sauter P. R., Goemann M., Coleman J., Grochow L., Donehower R. C., Lillemoe K. D., O'Reilly S., Abrams R. A., Pardoll D. M., Cameron J. L., Yeo C. J., Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation Journal of Clinical Oncology 2001 19 1 145 156
47. Aravindaram K., Yang N. S., Gene gun delivery systems for cancer vaccine approaches Methods in Molecular Biology 2009 542 167 178
48. Schwendener R. A., Ludewig B., Cerny A., Engler O., Liposome-based vaccines Methods in Molecular Biology 2010 605 163 175
49. Manickan E., Kanangat S., Rouse R. J. D., Yu Z., Rouse B. T., Enhancement of immune response to naked DNA vaccine by immunization with transfected dendritic cells Journal of Leukocyte Biology 1997 61 2 125 132
50. Sizemore D. R., Branstrom A. A., Sadoff J. C., Attenuated bacteria as a DNA delivery vehicle for DNA-mediated immunization Vaccine 1997 15 8 804 807
51. Ahmad S., Casey G., Sweeney P., Tangney M., O'Sullivan G. C., Optimised electroporation mediated DNA vaccination for treatment of prostate cancer Genetic Vaccines and Therapy 2010 8 1, article 1
52. Chiarella P., Fazio V. M., Signori E., Application of electroporation in DNA vaccination protocols Current Gene Therapy 2010 10 4 281 286
53. Heller L. C., Heller R., Electroporation gene therapy preclinical and clinical trials for melanoma Current Gene Therapy 2010 10 4 312 317
54. Low L., Mander A., McCann K., Dearnaley D., Tjelle T., Mathiesen I., Stevenson F., Ottensmeier C. H., DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer Human Gene Therapy 2009 20 11 1269 1278
55. Yi A.-K., Yoon J.-G., Hong S.-C., Redford T. W., Krieg A. M., Lipopolysaccharide and CpG DNA synergize for tumor necrosis factor- production through activation of NF- B International Immunology 2001 13 11 1391 1404
56. Akira S., Takeda K., Kaisho T., Toll-like receptors: critical proteins linking innate and acquired immunity Nature Immunology 2001 2 8 675 680
57. Medzhitov R., CpG DNA: security code for host defense Nature Immunology 2001 2 1 15 16
58. Yasuda K., Wagner H., Takakura Y., Role of immunostimulatory DNA and TLR9 in gene therapy Critical Reviews in Therapeutic Drug Carrier Systems 2006 23 2 89 109
59. Haas T., Metzger J., Schmitz F., Heit A., Mller T., Latz E., Wagner H., The DNA sugar backbone 2′ deoxyribose determines Toll-like receptor 9 activation Immunity 2008 28 3 315 323
60. Wagner H., The sweetness of the DNA backbone drives Toll-like receptor 9 Current Opinion in Immunology 2008 20 4 396 400
61. Ishii K. J., Coban C., Kato H., Takahashi K., Torii Y., Takeshita F., Ludwig H., Sutter G., Suzuki K., Hemmi H., Sato S., Yamamoto M., Uematsu S., Kawai T., Takeuchi O., Akira S., A toll-like receptor-independent antiviral response induced by double-stranded B-form DNA Nature Immunology 2006 7 1 40 48
62. Takaoka A., Wang Z., Choi M. K., Yanai H., Negishi H., Ban T., Lu Y., Miyagishi M., Kodama T., Honda K., Ohba Y., Taniguchi T., DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response Nature 2007 448 7152 501 505
63. Wang Z., Choi M. K., Ban T., Yanai H., Negishi H., Lu Y., Tamura T., Takaoka A., Nishikura K., Taniguchi T., Regulation of innate immune responses by DAI (DLM-1/ZBP1) and other DNA-sensing molecules Proceedings of the National Academy of Sciences of the United States of America 2008 105 14 5477 5482
64. Ishikawa H., Ma Z., Barber G. N., STING regulates intracellular DNA-mediated, type i interferon-dependent innate immunity Nature 2009 461 7265 788 792
65. Ablasser A., Bauernfeind F., Hartmann G., Latz E., Fitzgerald K. A., Hornung V., RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate Nature Immunology 2009 10 10 1065 1072
66. Chiu Y.-H., MacMillan J. B., Chen Z. J., RNA polymerase III detects cytosolic DNA and induces Type I interferons through the RIG-I pathway Cell 2009 138 3 576 591
67. Gurunathan S., Klinman D. M., Seder R. A., DNA vaccines: immunology, application, and optimization Annual Review of Immunology 2000 18 927 974
68. Liu M. A., DNA vaccines: a review Journal of Internal Medicine 2003 253 4 402 410
69. Darji A., Guzmn C. A., Gerstel B., Wachholz P., Timmis K. N., Wehland J., Chakraborty T., Weiss S., Oral somatic transgene vaccination using attenuated S. typhimurium Cell 1997 91 6 765 775
70. Paglia P., Medina E., Arioli I., Guzman C. A., Colombo M. P., Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimurium, results in protective immunity against a murine fibrosarcoma Blood 1998 92 9 3172 3176
71. Corr M., Lee D. J., Carson D. A., Tighe H., Gene vaccination with naked plasmid DNA: mechanism of CTL priming Journal of Experimental Medicine 1996 184 4 1555 1560
72. Ulmer J. B., Deck R. R., Dewitt C. M., Donnelly J. J., Liu M. A., Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by non-muscle cells Immunology 1996 89 1 59 67
73. Dudley M. E., Wunderlich J. R., Yang J. C., Sherry R. M., Topalian S. L., Restifo N. P., Royal R. E., Kammula U., White D. E., Mavroukakis S. A., Rogers L. J., Gracia G. J., Jones S. A., Mangiameli D. P., Pelletier M. M., Gea-Banacloche J., Robinson M. R., Berman D. M., Filie A. C., Abati A., Rosenberg S. A., Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma Journal of Clinical Oncology 2005 23 10 2346 2357
74. Powell D. J. Jr. , Dudley M. E., Hogan K. A., Wunderlich J. R., Rosenberg S. A., Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion Journal of Immunology 2006 177 9 6527 6539
75. Bourgeois C., Veiga-Fernandes H., Joret A.-M., Rocha B., Tanchot C., CD8 lethargy in the absence of CD4 help European Journal of Immunology 2002 32 8 2199 2207
76. Janssen E. M., Lemmens E. E., Wolfe T., Christen U., Von Herrath M. G., Schoenberger S. P., CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes Nature 2003 421 6925 852 856
77. Shedlock D. J., Shen H., Requirement for CD4 T cell help in generating functional CD8 T cell memory Science 2003 300 5617 337 339
78. Sun J. C., Bevan M. J., Defective CD8 T cell memory following acute infection without CD4 T cell help Science 2003 300 5617 339 342
79. Keusekotten K., Leonhardt R. M., Ehses S., Knittler M. R., Biogenesis of functional antigenic peptide transporter TAP requires assembly of pre-existing TAP1 with newly synthesized TAP2 Journal of Biological Chemistry 2006 281 26 17545 17551
80. Kloetzel P.-M., The proteasome and MHC class I antigen processing Biochimica et Biophysica Acta 2004 1695 13 225 233
81. Kovacsovics-Bankowski M., Rock K. L., A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules Science 1995 267 5195 243 246
82. Martinez A. N., Tenzer S., Schild H., T-cell epitope processing (the epitope flanking regions matter) Methods in Molecular Biology 2009 524 407 415
83. Kennedy R., Celis E., Multiple roles for CD4+ T cells in anti-tumor immune responses Immunological Reviews 2008 222 1 129 144
84. Yates A., Bergmann C., Leo Van Hemmen J., Stark J., Callard R., Cytokine-modulated regulation of helper T cell populations Journal of Theoretical Biology 2000 206 4 539 560
85. Tovey M. G., Lallemand C., Adjuvant activity of cytokines Methods in Molecular Biology 2010 626 287 309
86. Delogu G., Howard A., Collins F. M., Morris S. L., DNA vaccination against tuberculosis: expression of a ubiquitin- conjugated tuberculosis protein enhances antimycobacterial immunity Infection and Immunity 2000 68 6 3097 3102
87. Rodriguez F., Zhang J., Whitton J. L., DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction Journal of Virology 1997 71 11 8497 8503
88. Parkin D. M., Bray F., Ferlay J., Pisani P., Global cancer statistics, 2002 Cancer Journal for Clinicians 2005 55 2 74 108
89. Brinckerhoff L. H., Thompson L. W., Slingluff C. L. Jr. , Melanoma vaccines Current Opinion in Oncology 2000 12 2 163 173
90. Halama N., Zoernig I., Jaeger D., Advanced malignant melanoma: immunologic and multimodal therapeutic strategies Journal of Oncology 2010 2010 8
91. Chen Y.-T., Stockert E., Tsang S., Coplan K. A., Old L. J., Immunophenotyping of melanomas for tyrosinase: implications for vaccine development Proceedings of the National Academy of Sciences of the United States of America 1995 92 18 8125 8129
92. Prud'homme G. J., DNA vaccination against tumors Journal of Gene Medicine 2005 7 1 3 17
93. Parmiani G., Castelli C., Rivoltini L., Casati C., Tully G. A., Novellino L., Patuzzo A., Tosi D., Anichini A., Santinami M., Immunotherapy of melanoma Seminars in Cancer Biology 2003 13 6 391 400
94. Cassaday R. D., Sondel P. M., King D. M., Macklin M. D., Gan J., Warner T. F., Zuleger C. L., Bridges A. J., Schalch H. G., Kyung M. K., Hank J. A., Mahvi D. M., Albertini M. R., A phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients Clinical Cancer Research 2007 13 2, part I 540 549
95. Perales M.-A., Yuan J., Powel S., Gallardo H. F., Rasalan T. S., Gonzalez C., Manukian G., Wang J., Zhang Y., Chapman P. B., Krown S. E., Livingston P. O., Ejadi S., Panageas K. S., Engelhorn M. E., Terzulli S. L., Houghton A. N., Wolchok J. D., Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma Molecular Therapy 2008 16 12 2022 2029
96. Yuan J., Ku G. Y., Gallardo H. F., Orlandi F., Manukian G., Rasalan T. S., Xu Y., Li H., Vyas S., Mu Z., Chapman P. B., Krown S. E., Panageas K., Terzulli S. L., Old L. J., Houghton A. N., Wolchok J. D., Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma Cancer Immunity 2009 9, article 5
97. Triozzi P. L., Aldrich W., Allen K. O., Carlisle R. R., LoBuglio A. F., Conry R. M., Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse Journal of Immunotherapy 2005 28 4 382 388
98. Weber J., Boswell W., Smith J., Hersh E., Snively J., Diaz M., Miles S., Liu X., Obrocea M., Qiu Z., Bot A., Phase 1 trial of intranodal injection of a melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma Journal of Immunotherapy 2008 31 2 215 223
99. Meyer R. G., Britten C. M., Siepmann U., Petzold B., Sagban T. A., Lehr H. A., Weigle B., Schmitz M., Mateo L., Schmidt B., Bernhard H., Jakob T., Hein R., Schuler G., Schuler-Thurner B., Wagner S. N., Drexler I., Sutter G., Arndtz N., Chaplin P., Metz J., Enk A., Huber C., Wlfel T., A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr) Cancer Immunology, Immunotherapy 2005 54 5 453 467
100. Lindsey K. R., Gritz L., Sherry R., Abati A., Fetsch P. A., Goldfeder L. C., Gonzales M. I., Zinnack K. A., Rogers-Freezer L., Haworth L., Mavroukakis S. A., White D. E., Steinberg S. M., Restifo N. P., Panicali D. L., Rosenberg S. A., Topalian S. L., Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma Clinical Cancer Research 2006 12 8 2526 2527
101. Kochenderfer J. N., Gress R. E., A comparison and critical analysis of preclinical anticancer vaccination strategies Experimental Biology and Medicine 2007 232 9 1130 1141
102. Fang J., Lu Y., Ouyang K., Wu G., Zhang H., Liu Y., Chen Y., Lin M., Wang H., Jin L., Cao R., Roque R. S., Zong L., Liu J., Li T., Specific antibodies elicited by a novel DNA vaccine targeting gastrin-releasing peptide inhibit murine melanoma growth in vivo Clinical and Vaccine Immunology 2009 16 7 1033 1039
103. Sun X., Hodge L. M., Jones H. P., Tabor L., Simecka J. W., Co-expression of granulocyte-macrophage colony-stimulating factor with antigen enhances humoral and tumor immunity after DNA vaccination Vaccine 2002 20 9-10 1466 1474
104. Leslie M. C., Zhao Y. J., Lachman L. B., Hwu P., Bar-Eli M., Immunization against MUC18/MCAM, a novel antigen that drives melanoma invasion and metastasis Gene Therapy 2007 14 4 316 323
105. Schmollinger J. C., Dranoff G., Targeting melanoma inhibitor of apoptosis protein with cancer immunotherapy Apoptosis 2004 9 3 309 313
106. Lladser A., Ljungberg K., Tufvesson H., Tazzari M., Roos A.-K., Quest A. F. G., Kiessling R., Intradermal DNA electroporation induces survivin-specific CTLs, suppresses angiogenesis and confers protection against mouse melanoma Cancer Immunology, Immunotherapy 2010 59 1 81 92
107. Rocha-Zavaleta L., Alejandre J. E., Garcia-Carranca A., Parenteral and oral immunization with a plasmid DNA expressing the human papillomavirus 16-L1 gene induces systemic and mucosal antibodies and cytotoxic T lymphocyte responses Journal of Medical Virology 2002 66 1 86 95
108. Wang Y.-J., Hou Y., Huang H., Liu G.-R., White A. P., Liu S.-L., Two oral HBx vaccines delivered by live attenuated Salmonella: both eliciting effective anti-tumor immunity Cancer Letters 2008 263 1 67 76
109. Kamata M., Denda-Nagai K., Kubota N., Aida S., Takeda K., Irimura T., Vaccination of mice with MUC1 cDNA suppresses the development of lung metastases Clinical and Experimental Metastasis 2002 19 8 689 696
110. Seliger B., Wollscheid U., Momburg F., Blankenstein T., Huber C., Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells Cancer Research 2001 61 3 1095 1099
111. Peter I., Mezzacasa A., LeDonne P., Dummer R., Hemmi S., Comparative analysis of immunocritical melanoma markers in the mouse melanoma cell lines B16, K1735 and S91-M3 Melanoma Research 2001 11 1 21 30
112. Rakhmilevich A. L., Imboden M., Hao Z., Macklin M. D., Roberts T., Wright K. M., Albertini M. R., Yang N.-S., Sondel P. M., Effective particle-mediated vaccination against mouse melanoma by coadministration of plasmid DNA encoding gp100 and granulocyte-macrophage colony-stimulating factor Clinical Cancer Research 2001 7 4 952 961
113. Schreurs M. W. J., De Boer A. J., Figdor C. G., Adema G. J., Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection Cancer Research 1998 58 12 2509 2514
114. Zhou W.-Z., Kaneda Y., Huang S. K. S., Morishita R., Hoon D. S. B., Protective immunization against melanoma by gp100 DNA-HVJ-liposome vaccine Gene Therapy 1999 6 10 1768 1773
115. Nawrath M., Pavlovic J., Dummet R., Schultz J., Strack B., Heinrich J., Moelling K., Reduced melanoma tumor formation in mice immunized with DNA expressing the melanoma-specific antigen gp100/pmel17 Leukemia 1999 13 1 S48 S51
116. Weth R., Christ O., Stevanovic S., Zller M., Gene delivery by attenuated Salmonella typhimurium: comparing the efficacy of helper versus cytotoxic T cell priming in tumor vaccination Cancer Gene Therapy 2001 8 8 599 611
117. Cochlovius B., Stassar M. J. J. G., Schreurs M. W., Benner A., Adema G. J., Oral DNA vaccination: antigen uptake and presentation by dendritic cells elicits protective immunity Immunology Letters 2002 80 2 89 96
118. Hawkins W. G., Gold J. S., Dyall R., Wolchok J. D., Hoos A., Bowne W. B., Srinivasan R., Houghton A. N., Lewis J. J., Immunization with DNA coding for gp100 results in CD4+ T-cell independent antitumor immunity Surgery 2000 128 2 273 280
119. Gold J. S., Ferrone C. R., Guevara-Patio J. A., Hawkins W. G., Dyall R., Engelhorn M. E., Wolchok J. D., Lewis J. J., Houghton A. N., A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen Journal of Immunology 2003 170 10 5188 5194
120. Nawrath M., Pavlovic J., Moelling K., Synergistic effect of a combined DNA and peptide vaccine against gp100 in a malignant melanoma mouse model Journal of Molecular Medicine 2001 79 2 133 142
121. Elzaouk L., Pavlovic J., Moelling K., Analysis of antitumor activity elicited by vaccination with combinations of interleukin-12 DNA with gp100 DNA or the chemokine CCL21 in vivo Human Gene Therapy 2006 17 8 859 870
122. Wagner S. N., Wagner C., Lhrs P., Weimann T. K., Kutil R., Goos M., Stingl G., Schneeberger A., Intracutaneous genetic immunization with autologous melanoma-associated antigen Pmel17/gp100 induces T cell-mediated tumor protection in vivo Journal of Investigative Dermatology 2000 115 6 1082 1087
123. Weber L. W., Bowne W. B., Wolchok J. D., Srinivasan R., Qin J., Moroi Y., Clynes R., Song P., Lewis J. J., Houghton A. N., Tumor immunity and autoimmunity induced by immunization with homologous DNA Journal of Clinical Investigation 1998 102 6 1258 1264
124. Overwijk W. W., Lee D. S., Surman D. R., Irvine K. R., Touloukian C. E., Chan C.-C., Carroll M. W., Moss B., Rosenberg S. A., Restifo N. P., Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4+ T lymphocytes Proceedings of the National Academy of Sciences of the United States of America 1999 96 6 2982 2987
125. Saenger Y. M., Li Y., Chiou K. C., Chan B., Rizzuto G., Terzulli S. L., Merghoub T., Houghton A. N., Wolchok J. D., Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma Cancer Research 2008 68 23 9884 9891
126. Bronte V., Apolloni E., Ronca R., Zamboni P., Overwijk W. W., Surman D. R., Restifo N. P., Zanovello P., Genetic vaccination with 'self' tyrosinase-related protein 2 causes melanoma eradication but not vitiligo Cancer Research 2000 60 2 253 258
127. Bellone M., Cantarella D., Castiglioni P., Crosti M. C., Ronchetti A., Moro M., Garancini M. P., Casorati G., Dellabona P., Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma Journal of Immunology 2000 165 5 2651 2656
128. Hawkins W. G., Gold J. S., Blachere N. E., Bowne W. B., Hoos A., Lewis J. J., Houghton A. N., Xenogeneic DNA immunization in melanoma models for minimal residual disease Journal of Surgical Research 2002 102 2 137 143
129. Zhang M., Obata C., Hisaeda H., Ishii K., Murata S., Chiba T., Tanaka K., Li. Y., Furue M., Chou B., Imai T., Duan X., Himeno K., A novel DNA vaccine based on ubiquitin-proteasome pathway targeting 'self'-antigens expressed in melanoma/melanocyte Gene Therapy 2005 12 13 1049 1057
130. Dudley M. E., Wunderlich J. R., Robbins P. F., Yang J. C., Hwu P., Schwartzentruber D. J., Topalian S. L., Sherry R., Restifo N. P., Hubicki A. M., Robinson M. R., Raffeld M., Duray P., Seipp C. A., Rogers-Freezer L., Morton K. E., Mavroukakis S. A., White D. E., Rosenberg S. A., Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes Science 2002 298 5594 850 854
131. Morgan R. A., Dudley M. E., Wunderlich J. R., Hughes M. S., Yang J. C., Sherry R. M., Royal R. E., Topalan S. L., Kammula U. S., Restifo N. P., Zheng Z., Nahvi A., De Vries C. R., Rogers-Freezer L. J., Mavroukakis S. A., Rosenberg S. A., Cancer regression in patients after transfer of genetically engineered lymphocytes Science 2006 314 5796 126 129
132. Grinshtein N., Ventresca M., Margl R., Bernard D., Yang T.-C., Millar J. B., Hummel J., Beermann F., Wan Y., Bramson J. L., High-dose chemotherapy augments the efficacy of recombinant adenovirus vaccines and improves the therapeutic outcome Cancer Gene Therapy 2009 16 4 338 350
133. Zhu X., Cai J., Huang J., Jiang X., Ren D., The treatment and prevention of mouse melanoma with an oral dna vaccine carried by attenuated salmonella typhimurium Journal of Immunotherapy 2010 33 5 453 460
134. Bergman P. J., McKnight J., Novosad A., Charney S., Farrelly J., Craft D., Wulderk M., Jeffers Y., Sadelain M., Hohenhaus A. E., Segal N., Gregor P., Engelhorn M., Riviere I., Houghton A. N., Wolchok J. D., Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial Clinical Cancer Research 2003 9 4 1284 1290
135. Liao J. C., Gregor P., Wolchok J. D., Orlandi F., Craft D., Leung C., Houghton A. N., Bergman P. J., Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma Cancer Immunity 2006 6 8
136. Pritchard J., Cotterill S. J., Germond S. M., Imeson J., De Kraker J., Jones D. R., High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group Pediatric Blood and Cancer 2005 44 4 348 357
137. Volchenboum S. L., Cohn S. L., Progress in defining and treating high-risk neuroblastoma: lessons from the bench and bedside Journal of Clinical Oncology 2009 27 7 1003 1004
138. Yu A. L., Gilman A. L., Anti-GD2 antibody with GM-CSF, IL2 and isotretinoin for neuroblastoma: a children's oncology group (COG) phase III study New England Journal of Medicine 2010 363 14
139. Lode H. N., Xiang R., Varki N. M., Dolman C. S., Gillies S. D., Reisfeld R. A., Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow Journal of the National Cancer Institute 1997 89 21 1586 1594
140. Fest S., Huebener N., Weixler S., Bleeke M., Zeng Y., Strandsby A., Volkmer-Engert R., Landgraf C., Gaedicke G., Riemer A. B., Michalsky E., Jaeger I. S., Preissner R., Frster-Wald E., Jensen-Jarolim E., Lode H. N., Characterization of GD2 peptide mimotope DNA vaccines effective against spontaneous neuroblastoma metastases Cancer Research 2006 66 21 10567 10575
141. Kowalczyk A., Wierzbicki A., Gil M., Bambach B., Kaneko Y., Rokita H., Repasky E., Fenstermaker R., Brecher M., Ciesielski M., Kozbor D., Induction of protective immune responses against NXS2 neuroblastoma challenge in mice by immunotherapy with GD2 mimotope vaccine and IL-15 and IL-21 gene delivery Cancer Immunology, Immunotherapy 2007 56 9 1443 1458
142. Carpentier A. F., Rosenfeld M. R., Delattre J.-Y., Whalen R. G., Posner J. B., Dalmau J., DNA vaccination with HuD inhibits growth of a neuroblastoma in mice Clinical Cancer Research 1998 4 11 2819 2824
143. Lode H. N., Pertl U., Xiang R., Gaedicke G., Reisfeld R. A., Tyrosine hydroxylase-based DNA-vaccination is effective against murine neuroblastoma Medical and Pediatric Oncology 2000 35 6 641 646
144. Huebener N., Fest S., Strandsby A., Michalsky E., Preissner R., Zeng Y., Gaedicke G., Lode H. N., A rationally designed tyrosine hydroxylase DNA vaccine induces specific antineuroblastoma immunity Molecular Cancer Therapeutics 2008 7 7 2241 2251
145. Pertl U., Wodrich H., Ruehlmann J. M., Gillies S. D., Lode H. N., Reisfeld R. A., Immunotherapy with a posttranscriptionally modified DNA vaccine induces complete protection against metastatic neuroblastoma Blood 2003 101 2 649 654
146. Huebener N., Lange B., Lemmel C., Rammensee H. G., Strandsby A., Wenkel J., Jikai J., Zeng Y., Gaedicke G., Lode H. N., Vaccination with minigenes encoding for novel 'self' antigens are effective in DNA-vaccination against neuroblastoma Cancer Letters 2003 197 1-2 211 217
147. Fest S., Huebener N., Bleeke M., Durmus T., Stermann A., Woehler A., Baykan B., Zenclussen A. C., Michalsky E., Jaeger I. S., Preissner R., Hohn O., Weixler S., Gaedicke G., Lode H. N., Survivin minigene DNA vaccination is effective against neuroblastoma International Journal of Cancer 2009 125 1 104 114
148. Jemal A., Thomas A., Murray T., Thun M., Cancer statistics, 2002 Cancer Journal for Clinicians 2002 52 1 23 47
149. Crawford E. D., Rosenblum M., Ziada A. M., Lange P. H., Overview: hormone refractory prostate cancer Urology 1999 54 6A, supplement 1 7
150. Hillman G. G., Triest J. A., Cher M. L., Kocheril S. V., Talati B. R., Prospects of immunotherapy for the treatment of prostate carcinomaa review Cancer Detection and Prevention 1999 23 4 333 342
151. Tannock I. F., Osoba D., Stockler M. R., Ernst D. S., Neville A. J., Moore M. J., Armitage G. R., Wilson J. J., Venner P. M., Coppin C. M. L., Murphy K. C., Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points Journal of Clinical Oncology 1996 14 6 1756 1764
152. Noguchi M., Kobayashi K., Suetsugu N., Tomiyasu K., Suekane S., Yamada A., Itoh K., Noda S., Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination Prostate 2003 57 1 80 92
153. Garcia-Hernandez M. D. L. L., Gray A., Hubby B., Kast W. M., In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer Cancer Research 2007 67 3 1344 1351
154. Ross S., Spencer S. D., Holcomb I., Tan C., Hongo J., Devaux B., Rangell L., Keller G. A., Schow P., Steeves R. M., Lutz R. J., Frantz G., Hillan K., Peale F., Tobin P., Eberhard D., Rubin M. A., Lasky L. A., Koeppen H., Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate Cancer Research 2002 62 9 2546 2553
155. Zhu Z. Y., Zhong C. P., Xu W. F., Lin G. M., Ye G. Q. W., Ji Y. Y., Sun B., Yeh M., PSMA mimotope isolated from phage displayed peptide library can induce PSMA specific immune response Cell Research 1999 9 4 271 280
156. Wang Y., Harada M., Yano H., Ogasawara S., Takedatsu H., Arima Y., Matsueda S., Yamada A., Itoh K., Prostatic acid phosphatase as a target molecule in specific immunotherapy for patients with nonprostate adenocarcinoma Journal of Immunotherapy 2005 28 6 535 541
157. Todorova K., Ignatova I., Tchakarov S., Altankova I., Zoubak S., Kyurkchiev S., Mincheff M., Humoral immune response in prostate cancer patients after immunization with gene-based vaccines that encode for a protein that is proteasomally degraded Cancer Immunity 2005 5 1 8
158. Wolchok J. D., Gregor P. D., Nordquist L. T., Slovin S. F., Scher H. I., DNA vaccines: an active immunization strategy for prostate cancer Seminars in Oncology 2003 30 5 659 666
159. Mincheff M., Zoubak S., Makogonenko Y., Immune responses against PSMA after gene-based vaccination for immunotherapya: results from immunizations in animals Cancer Gene Therapy 2006 13 4 436 444
160. Roos A.-K., Pavlenko M., Charo J., Egevad L., Pisa P., Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine Prostate 2005 62 3 217 223
161. Marshall D. J., San Mateo L. R., Rudnick K. A., McCarthy S. G., Harris M. C., McCauley C., Schantz A., Geng D., Cawood P., Snyder L. A., Induction of Th1-type immunity and tumor protection with a prostate-specific antigen DNA vaccine Cancer Immunology, Immunotherapy 2005 54 11 1082 1094
162. Qin H., Zhou C., Wang D., Ma W., Liang X., Lin C., Zhang Y., Zhang S., Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens Immunology Letters 2005 99 1 85 93
163. Johnson L. E., Frye T. P., Chinnasamy N., Chinnasamy D., McNeel D. G., Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells Cancer Immunology, Immunotherapy 2007 56 6 885 895
164. Johnson L. E., Frye T. P., Arnot A. R., Marquette C., Couture L. A., Gendron-Fitzpatrick A., McNeel D. G., Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP) Vaccine 2006 24 3 293 303
165. McNeel D. G., Dunphy E. J., Davies J. G., Frye T. P., Johnson L. E., Staab M. J., Horvath D. L., Straus J., Alberti D., Marnocha R., Liu G., Eickhoff J. C., Wilding G., Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer Journal of Clinical Oncology 2009 27 25 4047 4054
166. Zhang X., Yu C., Zhao J., Fu L., Yi S., Liu S., Yu T., Chen W., Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice Journal of Gene Medicine 2007 9 8 715 726
167. Gingrich J. R., Barrios R. J., Morton R. A., Boyce B. F., DeMayo F. J., Finegold M. J., Angelopoulou R., Rosen J. M., Greenberg N. M., Metastatic prostate cancer in a transgenic mouse Cancer Research 1996 56 18 4096 4102
168. Greenberg N. M., DeMayo F., Finegold M. J., Medina D., Tilley W. D., Aspinall J. O., Cunha G. R., Donjacour A. A., Matusik R. J., Rosen J. M., Prostate cancer in a transgenic mouse Proceedings of the National Academy of Sciences of the United States of America 1995 92 8 3439 3443
169. Garcia-Hernandez M. D. L. L., Gray A., Hubby B., Klinger O. J., Kast W. M., Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity Cancer Research 2008 68 3 861 869
170. Ahmad S., Casey G., Sweeney P., Tangney M., O'Sullivan G. C., Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth Molecular Therapy 2009 17 6 1101 1108
171. Gray A., de la Luz Garcia-Hernandez M., van West M., Kanodia S., Hubby B., Kast W. M., Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages Vaccine 2009 27, supplement 6 G52 G59